Legal Updates

The New Jersey Supreme Court’s recent decision, Beavan v. Allergan U.S.A., Inc., 264 N.J. 99 (2026), represents a significant development in the state’s civil litigation framework, particularly regarding the admissibility of expert testimony. This pharmaceutical product liability dispute arises from plaintiff’s severe eye injuries allegedly caused by Allergan’s Ozurdex product, a drug delivery system that had been recalled due to silicone particulates detaching during injection. Central to the Court’s analysis was the reliability of the differential diagnosis methodology used by the plaintiff’s expert to establish causation. In its ruling, the Court reaffirmed the “rigorous” gatekeeping analysis established in In re Accutane Litigation, 234 N.J. 340 (2018), and clarified the trial court’s duty to evaluate expert testimony under a two-prong test before admitting it into evidence. Under this framework, trial courts must evaluate both (1) the soundness of the reasoning underlying the expert’s opinion, and (2) the reliability of the data and methodology used to support those opinions. This two-part test ensures that expert testimony rests on a solid foundation before juries are permitted to hear it.

The Two-Prong Reliability Test

The Beaven decision emphasizes that the gatekeeping mandated by New Jersey Rules of Evidence 702 and 703 requires trial courts to conduct an examination of both methodology and factual basis. The first prong focuses on the expert’s reasoning process, asking whether the analytical approach used is scientifically recognized and whether it aligns with methods generally accepted in the relevant field. The second prong requires the court to assess whether the expert has applied that methodology to reliable facts or data. An expert opinion that satisfies one prong but fails the other cannot be admitted.

This two-prong approach reflects the principle that expert testimony must meet dual standards of reliability: the method itself must be valid, and the expert must have employed it correctly using appropriate data. N.J.R.E. 702; N.J.R.E. 702. By requiring trial courts to scrutinize both dimensions, the Court ensures that experts conclusions are grounded in the specific facts of the case and supported by data of the type reasonably relied upon by experts in the field. N.J.R.E. 703.

Differential Diagnosis and the Net Opinion Rule

A key aspect of the decision was the Court’s clarification of the differential diagnosis methodology. While the Court acknowledged that a differential diagnosis can be a valid method for proving causation in medical cases, it emphasized that the methodology must be applied reliably and supported by factual evidence. The Court also reiterated the prohibition against “net opinions,” which are expert conclusions unsupported by data or factual evidence. By rejecting speculative or inadequately supported expert testimony, the decision underscores the importance of a sound factual foundation for expert opinions in civil litigation.

Broader Impact on New Jersey Civil Litigation

The broader impact of the decision lies in its extension of the Accutane gatekeeping framework to all civil cases in New Jersey, not just product liability actions. This universal application raises the standard for admitting expert testimony across all types of civil litigation, ensuring greater consistency and reliability in evidentiary rulings. The decision also places a heavier burden on plaintiffs to meet stricter reliability requirements for their expert witnesses, potentially reshaping litigation strategies and outcomes in New Jersey. By enhancing the trial courts’ role as gatekeepers, the ruling aims to ensure that only scientifically valid and reliable expert evidence is presented to juries, thereby promoting fairness and accuracy in the judicial process.